Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

• Published in: The New England journal of medicine Vol. 387; no. 2; pp. 132 - 147
• Main Authors: Richardson, Paul G., Jacobus, Susanna J., Weller, Edie A., Hassoun, Hani, Lonial, Sagar, Raje, Noopur S., Medvedova, Eva, McCarthy, Philip L., Libby, Edward N., Voorhees, Peter M., Orlowski, Robert Z., Anderson, Larry D., Zonder, Jeffrey A., Milner, Carter P., Gasparetto, Cristina, Agha, Mounzer E., Khan, Abdullah M., Hurd, David D., Gowin, Krisstina, Kamble, Rammurti T., Jagannath, Sundar, Nathwani, Nitya, Alsina, Melissa, Cornell, R. Frank, Hashmi, Hamza, Campagnaro, Erica L., Andreescu, Astrid C., Gentile, Teresa, Liedtke, Michaela, Godby, Kelly N., Cohen, Adam D., Openshaw, Thomas H., Pasquini, Marcelo C., Giralt, Sergio A., Kaufman, Jonathan L., Yee, Andrew J., Scott, Emma, Torka, Pallawi, Foley, Amy, Fulciniti, Mariateresa, Hebert, Kyle, Samur, Mehmet K., Masone, Kelly, Maglio, Michelle E., Zeytoonjian, Andrea A., Nadeem, Omar, Schlossman, Robert L., Laubach, Jacob P., Paba-Prada, Claudia, Ghobrial, Irene M., Perrot, Aurore, Moreau, Philippe, Avet-Loiseau, Hervé, Attal, Michel, Anderson, Kenneth C., Munshi, Nikhil C.
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 14-07-2022
• Subjects: Adult; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Autografts; Bone marrow; Bone Marrow Transplantation; Bortezomib; Bortezomib - administration & dosage; Bortezomib - adverse effects; Cancer; Confidence intervals; Dexamethasone; Dexamethasone - administration & dosage; Dexamethasone - adverse effects; Disease Progression; Disease-Free Survival; Hematology; Humans; Inhibitor drugs; Lenalidomide - administration & dosage; Lenalidomide - adverse effects; Leukemia; Lymphoma; Maintenance Chemotherapy - methods; Medical prognosis; Melphalan; Melphalan - administration & dosage; Multiple myeloma; Multiple Myeloma - diagnosis; Multiple Myeloma - drug therapy; Multiple Myeloma - surgery; Oncology; Patients; Quality of life; Stem Cell Transplantation; Targeted cancer therapy; Transplantation, Autologous; Treatments in Oncology
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa2204925

In a large, multinational, randomized trial, continuous lenalidomide maintenance therapy after triplet therapy (lenalidomide, bortezomib, and dexamethasone) and autologous stem-cell transplantation resulted in longer progression-free survival than triplet therapy alone.